NR2F6 and hepatoblastoma: Further, an evidence-based model, including 219 hepatoblastoma samples and 121 non-cancer liver tissues, was performed to assess the expression of NR2F6, from which NR2F6 was also found to be overexpressed in hepatoblastoma compared with non-cancer liver with a standard mean difference (SMD) of 1.04 (95% CI: 0.79, 1.29; heterogeneity: 1%; random-effects model; Figure 2(a)).